EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability

Brenna Champlin, Katherine Keefe, Andrew C Birkeland, Shiruyeh Schokrpur

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2600408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Brenna Champlin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Davis School of Medicine, University of California, Sacramento, CA, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Paul Calabresi K12.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) remains a treatment challenge, with frequent recurrences following localized disease and guarded outcomes in recurrent/metastatic (R/M) settings. While cytotoxic therapy and immune checkpoint inhibitors (ICIs) have produced incremental survival benefits, many patients still exhibit limited response or acquire resistance to treatment, highlighting a critical need for more personalized and novel therapeutic strategies. AREAS COVERED: This review discusses personalized therapy approaches in HNSCC from 2020 to 2025, focusing on immune checkpoint blockade and newer therapeutic modalities. Additionally, this review highlights key biomarkers that are currently being evaluated for predictive and prognostic value in HNSCC. The literature was sourced through PubMed, Google Scholar, and conference abstracts from ASCO, ESMO, and AACR, covering publications from January 2020-June 2025, with a focus on peer-reviewed trials and translational studies in human subjects. EXPERT OPINION: The future of HNSCC treatment lies in the development of novel treatment combinations integrating immunotherapy using immune checkpoint blockade with newer therapeutic approaches. Understanding which agents to use, and when in the course of treatment, stands as a challenge that will shape the future of precision therapy for HNSCC, with integration of biomarkers promising to guide this transition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAntineoplastic AgentsHumansPrecision MedicineImmune Checkpoint InhibitorsImmunotherapyBiomarkers, TumorPrognosisAnimalsDrug Resistance, NeoplasmNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Antibody-drug conjugates (ADCs)PD-L1 combined positive score (CPS)bispecific antibodiescheckpoint inhibitorshead and neck squamous cell carcinoma (HNSCC)immunotherapynivolumabprecision oncology

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Davis School of Medicine, University of California, Sacramento, CA, USA.
  • Department of Otolaryngology-Head and Neck Surgery, University of California, Sacramento, CA, USA.
  • Department of Internal Medicine, Division of Hematology/Oncology, University of California, Sacramento, CA, USA.

Förderung

  • NCI NIH HHS
  • Paul Calabresi K12

Zitieren

APA

Champlin, B., Keefe, K., Birkeland, A. C., & Schokrpur, S. (2025). The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2600408

Vancouver

Champlin B, Keefe K, Birkeland AC, Schokrpur S. The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2600408

BibTeX
@article{Champlin2025,
  author = {Champlin, Brenna and Keefe, Katherine and Birkeland, Andrew C and Schokrpur, Shiruyeh},
  title = {The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2600408}
}
Kostenlos starten →